Archives: 2023-11-13

VERVE-101: CRISPR-Based Gene Editing Therapy Shows Promise in Reducing LDL-C and PCSK9 Levels in Patients With HeFH

A single infusion of a CRISPR-based gene editing therapy significantly reduced LDL-C and PCSK9 levels in patients with heterozygous familial hypercholesterolemia (HeFH), based on findings from the VERVE-101 trial presented Nov. 12 at AHA 2023. In presenting the findings, Andrew Bellinger, MD, PhD, said they provide the first proof-of-concept for in vivo DNA base editing in humans.

Read More


Semaglutide 2.4 mg delivered a statistically significant 20% risk reduction in major adverse cardiovascular events

Semaglutide 2.4 mg (Wegovy®) cardiovascular outcomes data presented at American Heart Association Scientific Sessions and simultaneously published in New England Journal of Medicine At the American Heart Asoociation annual Scientific Session were announced the primary results of SELECT, its landmark phase 3 cardiovascular outcomes trial investigating the effects of once-weekly semaglutide 2.4 mg (Wegovy®) in

Read More


COVID Moonshot Consortium Unveils Crowd-Sourced Covid Antiviral Lead Compound

The work of the COVID Moonshot Consortium is being published in the prestigious journal Science on 10 November, revealing their discovery of a potent SARS-CoV-2 antiviral lead compound. It also reflects on the success of its open science approach in launching a patent-free antiviral discovery program to rapidly develop a differentiated lead in response to

Read More


FDA Approves First Treatment for Patients with Rare Congenital Thrombotic Thrombocytopenic Purpura

The U.S. Food and Drug Administration approved Adzynma, the first recombinant (genetically engineered) protein product indicated for prophylactic (preventive) or on demand enzyme replacement therapy (ERT) in adult and pediatric patients with congenital thrombotic thrombocytopenic purpura (cTTP), a rare and life-threatening blood clotting disorder. “The FDA remains deeply committed in our efforts to help facilitate

Read More


November the 10th Updated living WHO guideline on drugs for covid-19

November the 10th a panel of international experts representing the World Health Organization’s Guideline Development Group has updated its guidance on treatments for patients with COVID-19. The new recommendations published by The BMJ are part of a living guideline, developed by the World Health Organization with the methodological support of MAGIC Evidence Ecosystem Foundation, to provide up

Read More


Leading cardiologists reveal new heart disease risk calculator

Cardiovascular, kidney and metabolic health measures included in new PREVENT risk calculator, detailed in a new American Heart Association Scientific Statement Statement Highlights: A new calculator estimates a person’s risk for cardiovascular disease (CVD) over the next 30 years by combining measures of cardiovascular, kidney and metabolic health for the first time, according to a

Read More


New Study: Gargling and Nasal Rinsing with Salt Water May Help Prevent Covid Hospitalization

Hospitalization rates in people with saline regimens significantly lower than in reference population  As Covid and its health effects move into a fourth year, those who become infected may be searching for remedies to improve their respiratory symptoms and keep them out of the hospital. A new study being presented at this year’s American College

Read More